Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Micrus Endovascular Corp.

FT is investigating potential claims on behalf of shareholders of Micrus Endovascular Corp. (NasdaqGM:MEND) arising from the Company's announcement of its intent to be acquired by Johnson & Johnson (NYSE:JNJ). Under the terms of the agreement, Micrus shareholders will receive $23.40 in cash for each Micrus share of common stock they own, for a total transaction value of approximately $480 million.

The investigation is focused on the potential unfairness of the consideration to Micrus shareholders and the process by which the Company's Board of Directors considered and approved the transaction. In particular, Micrus earned approximately $91.1 million in the first three months in 2010 compared to $78.2 million in 2009. Furthermore, Micrus’ SEC filings indicate the company’s intent to broaden its product line and further expand its products worldwide. Micrus shares traded as high as $22.29 on July 9, 2010, and according to Yahoo Finance, at least one analyst has set a target price for Micrus stock of $25.00 per share.

If you are interested in discussing your rights as a Micrus shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it .